Profil bibliographique

Chiara Viganò

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

113Publications signalées

1470Citations signalées

3Affiliations récentes

Institutions déclarées

Ospedale di Circolo e Fondazione Macchi Azienda Ospedaliera San Gerardo University of Milano-Bicocca

Domaines associés

Inflammatory Bowel DiseaseMicroscopic ColitisRetinal Diseases and TreatmentsCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Publications récentes

2026 articleOpenAlex

Real‐World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease—A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases ( IG ‐ IBD )

Brigida Barberio, Ferdinando D’Amico, Lucrezia Laterza, Cristina Bezzio et autres

0 citationsAlimentary Pharmacology & Therapeutics

Accès ouvert 2026 articleOpenAlex

Pancreatic Hyperenzymemia in Inflammatory Bowel Disease: Clinical Characterization and Outcomes from the European PANDORA Registry

Salvatore Crucillà, Asia Berlato, Antonietta Gerarda Gravina, Anneline Cremer et autres

0 citationsPathophysiology

Accès ouvert 2026 articleOpenAlex

ACNMD26-173: REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC THERAPIES IN BIOLOGIC-NAÏVE PATIENTS WITH ULCERATIVE COLITIS

Cristina Bezzio, Federica Furfaro, Giuseppe Privitera, Silvia Ferretti et autres

0 citationsDigestive and Liver Disease

Accès ouvert 2026 articleOpenAlex

Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study

Franco Scaldaferri, Federica Di Vincenzo, M Aloi, M. Ascolani et autres

4 citationsThe American Journal of Gastroenterology

Accès ouvert 2026 articleOpenAlex

Adherence of glaucoma intervention studies to World Glaucoma Association guidelines

Andrea Servillo, Carlo Alberto Cutolo, Chiara Viganò, Paolo Forte et autres

1 citationActa Ophthalmologica

Accès ouvert 2026 articleOpenAlex

Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial

L. Cristoferi, Daphne D’Amato, Cesare Maino, D. Bernasconi et autres

2 citationsBMJ Open

Accès ouvert 2025 articleOpenAlex

Inflammatory Bowel Disease: Understanding Therapeutic Effects of Distinct Molecular Inhibitors as the Key to Current and Future Advanced Therapeutic Strategies

Alice Laffusa, Cesare Burti, Chiara Viganò, Francesca Poggi et autres

8 citationsBiomedicines

Accès ouvert 2025 articleOpenAlex

Acute Pancreatitis in Inflammatory Bowel Disease: Results from the European Pandora Study

Maria Cristina Conti Bellocchi, Martina Cattani Mottes, Andreas Blesl, Anneline Cremer et autres

2 citationsMedicina

2025 articleOpenAlex

Sa1937: FIDAXOMICIN FOR CLOSTRIDIODES DIFFICILE INFECTION IN INFLAMMATORY BOWEL DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY

Daniele Noviello, María Chaparro, Chiara Viganò, Andreas Blesl et autres

0 citationsGastroenterology

Accès ouvert 2025 articleOpenAlex

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

Daniele Noviello, María Chaparro, Chiara Viganò, Andreas Blesl et autres

2 citationsJournal of Crohn s and Colitis

2025 conference-paperOpenAlex

Safety and efficacy of Upadacitinib in patients with primary sclerosing cholangitis: a multicentre, retrospective study

Ida Schregel, Emma Culver, Senamjit Kaur, Palak Trivedi et autres

0 citationsZeitschrift für Gastroenterologie

Accès ouvert 2025 articleOpenAlex

P1156 Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease: a multicenter retrospective cohort study

Daniele Noviello, María Chaparro, Chiara Viganò, Andreas Blesl et autres

0 citationsJournal of Crohn s and Colitis

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.